Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constitutive DUSP2 expression enhances lymphoid cell proliferation by activating CDK1 and promotes lymphomagenesis.

Cell reports·2026
Same author

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

BMC medicine·2026
Same author

Transgenic expression of human signal regulatory protein alpha (SIRPα) in BALB/c Rag2<sup>null</sup>/Jak3<sup>null</sup> immunodeficient mice enhances human lymphoma xenografts by reducing phagocytosis.

Transgenic research·2026
Same author

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Elotuzumab enhances the anti-tumor activity of Vγ9Vδ2 T cells against primary effusion lymphoma.

European journal of pharmacology·2026

Related Experiment Video

Updated: Mar 9, 2026

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.7K

Tyrosine kinase/phosphatase inhibitors decrease dengue virus production in HepG2 cells.

Thawornchai Limjindaporn1, Jutatip Panaampon1, Shilu Malakar2

  • 1Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Biochemical and Biophysical Research Communications
|January 10, 2017
PubMed
Summary

Researchers identified compounds that inhibit dengue virus (DENV) replication. Epidermal growth factor receptor and protein tyrosine phosphatase inhibitors significantly reduced DENV production with low toxicity in liver cells.

Keywords:
Antiviral activityDengue virusEpidermal growth factor receptor inhibitorHepG2 cellsProtein tyrosine phosphatase inhibitor

More Related Videos

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

7.2K
Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

19.2K

Related Experiment Videos

Last Updated: Mar 9, 2026

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.7K
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

7.2K
Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

19.2K

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Dengue virus causes severe febrile illnesses, including dengue hemorrhagic fever and shock syndrome.
  • Disease severity correlates with high dengue virus replication and virion production.

Purpose of the Study:

  • To identify novel compounds with anti-dengue virus (DENV) activity.
  • To evaluate the efficacy and toxicity of potential DENV inhibitors.

Main Methods:

  • Cell-based ELISA was used to measure DENV E protein expression as a proxy for viral replication.
  • Screening of 83 potential inhibitors was conducted.
  • Toxicity was assessed in hepatocyte cell lines (HepG2).

Main Results:

  • Eight inhibitors demonstrated antiviral activity against DENV.
  • Epidermal growth factor receptor inhibitor II and protein tyrosine phosphatase inhibitor IV significantly reduced DENV production.
  • These two inhibitors exhibited low toxicity in HepG2 cells.

Conclusions:

  • Tyrosine kinase and phosphatase inhibitors show promise for reducing dengue virus production.
  • EGFR/ErbB-2/ErbB-4 inhibitor II and PTP inhibitor IV are potential candidates for further dengue therapeutic development.